{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:43:22Z","timestamp":1787453002762,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":1662,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1194\/jlr.r052258","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T08:17:35Z","timestamp":1456820255000},"page":"340-351","source":"Crossref","is-referenced-by-count":124,"title":["Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans"],"prefix":"10.1016","volume":"57","author":[{"given":"Mark J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne M.","family":"Crooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.R052258_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1194\/jlr.R052258_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature."},{"key":"10.1194\/jlr.R052258_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R052258_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA."},{"key":"10.1194\/jlr.R052258_bib5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation."},{"key":"10.1194\/jlr.R052258_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0b013e32835111d8","article-title":"Lipoprotein(a): more interesting than ever after 50 years","volume":"23","author":"Dub\u00e9","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R052258_bib11","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R052258_bib12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/ATVBAHA.112.251306","article-title":"Mechanisms of lipoprotein(a) pathogenicity","volume":"32","author":"Spence","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R052258_bib14","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R052258_bib15","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R052258_bib16","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M036343","article-title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma","volume":"54","author":"Wiesner","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R052258_bib17","first-page":"1444","article-title":"Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?","volume":"2","author":"Henry","year":"2001","journal-title":"Curr. Opin. Investig. Drugs."},{"key":"10.1194\/jlr.R052258_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"10.1194\/jlr.R052258_bib19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.R052258_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmaco\u00adkinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1194\/jlr.R052258_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(\u00ae)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1194\/jlr.R052258_bib22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1194\/jlr.R052258_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1194\/jlr.R052258_bib24","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1194\/jlr.R052258_bib28","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1161\/01.CIR.98.18.1898","article-title":"Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression","volume":"98","author":"Morishita","year":"1998","journal-title":"Circu\u00adlation."},{"key":"10.1194\/jlr.R052258_bib29","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation."},{"key":"10.1194\/jlr.R052258_bib31","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet."},{"key":"10.1194\/jlr.R052258_bib32","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One."},{"key":"10.1194\/jlr.R052258_bib33","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation."},{"key":"10.1194\/jlr.R052258_bib34","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R052258_bib36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1194\/jlr.M400467-JLR200","article-title":"High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins","volume":"46","author":"Schneider","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R052258_bib37","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R052258_bib38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib39","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jacc.2012.08.979","article-title":"Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib40","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","article-title":"Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans","volume":"63","author":"Ravandi","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib41","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib42","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng0495-424","article-title":"The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice","volume":"9","author":"Frazer","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1194\/jlr.R052258_bib44","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1016\/S0021-9258(18)92782-1","article-title":"Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model","volume":"266","author":"Azrolan","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R052258_bib45","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1172\/JCI114395","article-title":"Plasma lp(a) concentration is inversely correlated with the ratio of Kringle IV\/Kringle V encoding domains in the apo(a) gene","volume":"84","author":"Gavish","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R052258_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"\u2018LDL-C\u2019 = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R052258_bib47","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R052258_bib48","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R052258_bib49","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet."},{"key":"10.1194\/jlr.R052258_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/jca.21356","article-title":"Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis","volume":"30","author":"Safarova","year":"2015","journal-title":"J. Clin. Apher."},{"key":"10.1194\/jlr.R052258_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.atherosclerosissup.2015.02.019","article-title":"The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial","volume":"18","author":"Khan","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1194\/jlr.R052258_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosissup.2015.02.006","article-title":"First data from the German Lipoprotein Apheresis Registry (GLAR)","volume":"18","author":"Schettler","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1194\/jlr.R052258_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosissup.2015.02.033","article-title":"Effects of lipoprotein apheresis on the lipoprotein(a) levels in the long run","volume":"18","author":"Gro\u00df","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"10.1194\/jlr.R052258_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11789-015-0071-3","article-title":"Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease","volume":"10","author":"Heigl","year":"2015","journal-title":"Clin. Res. Cardiol. Suppl."},{"key":"10.1194\/jlr.R052258_bib56","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation."},{"key":"10.1194\/jlr.R052258_bib57","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R052258_bib58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2012.073833","article-title":"Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children","volume":"98","author":"Goldenberg","year":"2013","journal-title":"Haematologica."},{"key":"10.1194\/jlr.R052258_bib59","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1194\/jlr.R052258_bib60","doi-asserted-by":"crossref","first-page":"17125","DOI":"10.1073\/pnas.0508537102","article-title":"The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc","volume":"102","author":"Park","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R052258_bib61","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.1995.75.3.591","article-title":"The asialoglycoprotein receptor: relationships between structure, function, and expression","volume":"75","author":"Stockert","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1194\/jlr.R052258_bib62","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence mounts for a role of the kidney in lipoprotein(a) catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int."}],"updated-by":[{"DOI":"10.1194\/jlr.r052258err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000}}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752035433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002222752035433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.R052258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T19:07:35Z","timestamp":1637435255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002222752035433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S002222752035433X"],"URL":"https:\/\/doi.org\/10.1194\/jlr.r052258","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}